

Gisbert W Selke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6996080/publications.pdf>

Version: 2024-02-01

17
papers

862
citations

687363

13
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

846
citing authors

#	ARTICLE	IF	CITATIONS
1	Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 527-540.	1.4	48
2	Trends and patterns in EU(7)-PIM prescribing to elderly patients in Germany. European Journal of Clinical Pharmacology, 2021, 77, 1553-1561.	1.9	10
3	Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications. BioMed Research International, 2021, 2021, 1-16.	1.9	7
4	Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab. Applied Health Economics and Health Policy, 2020, 18, 5-16.	2.1	31
5	Integrative Review of Managed Entry Agreements: Chances and Limitations. Pharmacoeconomics, 2020, 38, 1165-1185.	3.3	25
6	Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany. Pharmaceuticals, 2020, 13, 324.	3.8	20
7	The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures. Frontiers in Pharmacology, 2020, 11, 591134.	3.5	44
8	Impact of EU risk assessment process and administrative regulations for manufacturers of combined hormonal contraceptive prescribing. An analysis of developments in Germany and the implications. Current Medical Research and Opinion, 2019, 35, 697-704.	1.9	3
9	Pricing of oral generic cancer medicines in 25 European countries; findings and implications. GaBI Journal, 2019, 8, 49-70.	0.3	31
10	Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. Frontiers in Public Health, 2018, 6, 328.	2.7	102
11	Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation. Frontiers in Pharmacology, 2017, 8, 497.	3.5	34
12	Policies for biosimilar uptake in Europe: An overview. PLoS ONE, 2017, 12, e0190147.	2.5	153
13	Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?. Expert Review of Clinical Pharmacology, 2015, 8, 77-94.	3.1	108
14	Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future. GaBI Journal, 2015, 4, 125-135.	0.3	10
15	Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. Frontiers in Pharmacology, 2014, 5, 109.	3.5	44
16	Personalizing health care: feasibility and future implications. BMC Medicine, 2013, 11, 179.	5.5	81
17	Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Frontiers in Pharmacology, 2013, 4, 39.	3.5	75